A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine

• Published in: Clinical therapeutics Vol. 23; no. 7; pp. 1040 - 1058
• Main Authors: Coleman, Charles C., King, Benjamin R., Bolden-Watson, Carolyn, Book, Martin J., Taylor Segraves, R., Richard, Nathalie, Ascher, John, Batey, Sharyn, Jamerson, Brenda, Metz, Alan
• Format: Journal Article
• Language: English
• Published: Belle Mead, NJ EM Inc USA 01.07.2001; Excerpta Medica
• Subjects: Adult; antidepressant; Antidepressive Agents, Second-Generation - therapeutic use; Biological and medical sciences; Bupropion - adverse effects; Bupropion - therapeutic use; bupropion sustained release; Delayed-Action Preparations; depression; Depressive Disorder - drug therapy; Double-Blind Method; Female; fluoxetine; Fluoxetine - adverse effects; Fluoxetine - therapeutic use; Humans; Male; Medical sciences; Multicenter Studies as Topic; Neuropharmacology; Patient Compliance; Patient Satisfaction; Pharmacology. Drug treatments; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychology. Psychoanalysis. Psychiatry; Psychopharmacology; sexual dysfunction; Sexual Dysfunction, Physiological - chemically induced; bupropion sustained release; fluoxetine; sexual dysfunction; depression; antidepressant; Mood disorder; Human; Amfebutamone; Dopamine; Serotonin; Fluoxetine; Controlled release form; Psychotropic; Toxicity; Treatment efficiency; Depression; Catecholamine; Reuptake inhibitor; Genital diseases; Chemotherapy; Treatment; Sexuality; Dosage form; Norepinephrine; Comparative study
• ISSN: 0149-2918; 1879-114X
• DOI: 10.1016/S0149-2918(01)80090-4

Background: Many antidepressants are associated with sexual dysfunction, a side effect that may lead to patients' dissatisfaction and noncompliance with treatment. Objective: This study compared the efficacy, tolerability, and effects on sexual functioning of bupropion sustained release (bupropion SR) and the selective serotonin reuptake inhibitor fluoxetine. Methods: In this multicenter, randomized, double-blind, double-dummy, parallel-group study, patients with recurrent major depression were treated with bupropion SR 150 to 400 mg/d, fluoxetine 20 to 60 mg/d, or placebo for up to 8 weeks. Depression and sexual-functioning status were assessed by site-specific trained investigators at weekly clinic visits; tolerability was assessed primarily by monitoring adverse events. Results: Four hundred fifty-six patients participated in the study, 150 receiving bupropion SR, 154 fluoxetine, and 152 placebo. The majority of patients in each group completed the study (63% each, bupropion SR [n = 94] and fluoxetine [n = 97]; 67%, placebo [n = 102]). Bupropion SR and fluoxetine were similarly effective in the treatment of depressive symptoms. Beginning at week 2 and continuing throughout the study, significantly more fluoxetine-treated patients experienced orgasm dysfunction than did patients receiving bupropion SR or placebo ( P < 0.001); similar results were seen in patients defined as clinical responders (≥50% decrease from baseline in 21-item Hamilton Rating Scale for Depression [HAM-D] total score) ( P < 0.001) and in those experiencing remission of depression (HAM-D total score <8) ( P < 0.05). At various time points, worsened sexual functioning, sexual desire disorder, sexual arousal disorder, and dissatisfaction with sexual functioning in those satisfied at baseline were more frequently associated with fluoxetine treatment than with bupropion SR or placebo. Both active treatments were well tolerated. Conclusions: Bupropion SR and fluoxetine were similarly effective and well tolerated in the treatment of depression. Fluoxetine, however, was more frequently associated with sexual dysfunction compared with bupropion SR. Bupropion SR may be an appropriate initial choice for the treatment of depression in patients concerned about sexual functioning.